David Alastair Flockhart
#150,525
Most Influential Person Now
David Alastair Flockhart's AcademicInfluence.com Rankings
David Alastair Flockhartmedical Degrees
Medical
#2895
World Rank
#3339
Historical Rank
Pharmacology
#330
World Rank
#381
Historical Rank

Download Badge
Medical
Why Is David Alastair Flockhart Influential?
(Suggest an Edit or Addition)David Alastair Flockhart's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. (2005) (932)
- Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism (2002) (907)
- Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. (2003) (837)
- Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. (2005) (769)
- Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6 (2004) (636)
- The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity (2003) (612)
- Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. (2008) (611)
- The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen (2006) (577)
- Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment (2006) (468)
- Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen (2004) (447)
- Studies on the properties and mode of action of the purified regulatory subunit of bovine heart adenosine 3':5'-monophosphate-dependent protein kinase. (1978) (338)
- Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. (2001) (307)
- Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. (2001) (303)
- Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen (2005) (296)
- Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. (2012) (290)
- Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges (2007) (286)
- Regulatory mechanisms in the control of protein kinases. (1982) (282)
- Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. (2006) (277)
- Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. (2010) (231)
- Inhibition of IL-12 production by thalidomide. (1997) (229)
- Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. (1997) (228)
- Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. (2007) (226)
- Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin (2008) (216)
- Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. (2010) (199)
- Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors (2008) (196)
- Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. (1999) (191)
- Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. (2011) (183)
- The IGNITE network: a model for genomic medicine implementation and research (2015) (180)
- CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations (2013) (176)
- Inhibition of Cytochrome P450 (CYP450) Isoforms by Isoniazid: Potent Inhibition of CYP2C19 and CYP3A (2001) (174)
- The emerging role of cytochrome P450 3A in psychopharmacology. (1995) (171)
- Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. (2004) (168)
- Pharmacogenomics: Challenges and Opportunities (2006) (162)
- The hydroxylation of omeprazole correlates with S‐mephenytoin metabolism: A population study (1995) (162)
- Endoxifen, a Secondary Metabolite of Tamoxifen, and 4-OH-Tamoxifen Induce Similar Changes in Global Gene Expression Patterns in MCF-7 Breast Cancer Cells (2006) (160)
- Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. (1999) (152)
- Greater quinidine‐induced QTc interval prolongation in women (2000) (144)
- Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. (1998) (141)
- Implications of cytochrome P450 interactions when prescribing medication for hypertension. (2002) (139)
- Impact of Proton Pump Inhibitors on the Effectiveness of Clopidogrel After Coronary Stent Placement: The Clopidogrel Medco Outcomes Study (2010) (129)
- Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting (2016) (129)
- Drug‐metabolizing enzymes: Evidence for clinical utility of pharmacogenomic tests (2005) (121)
- The Dual Role of Pharmacogenetics in HIV Treatment: Mutations and Polymorphisms Regulating Antiretroviral Drug Resistance and Disposition (2012) (120)
- Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6) (1999) (115)
- Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. (2002) (115)
- Endothelial nitric oxide synthase gene haplotypes associated with circulating concentrations of nitric oxide products in healthy men (2005) (114)
- Effects of endothelial nitric oxide synthase gene polymorphisms on platelet function, nitric oxide release, and interactions with estradiol. (2002) (114)
- Pharmacokinetic and Pharmacodynamic Consequences of Metabolism‐Based Drug Interactions with Alprazolam, Midazolam, and Triazolam (1999) (113)
- High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. (2003) (112)
- In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6. (2000) (112)
- Drug Interactions and the Cytochrome P450 System (1995) (112)
- Cytochrome P450-mediated drug interactions. (2000) (112)
- Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients (2010) (112)
- VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. (2008) (110)
- The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. (2001) (108)
- Literature Based Drug Interaction Prediction with Clinical Assessment Using Electronic Medical Records: Novel Myopathy Associated Drug Interactions (2012) (102)
- Abstract 3998: Proton Pump Inhibitors Effect on Clopidogrel Effectiveness: The Clopidogrel Medco Outcomes Study (2008) (99)
- Variability of heart rate correction methods for the QT interval. (2003) (97)
- Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. (2008) (95)
- Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. (2002) (95)
- Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199 (2015) (91)
- Association Between the CYP3A5 Genotype and Blood Pressure (2005) (91)
- PharmGKB summary: tamoxifen pathway, pharmacokinetics (2013) (90)
- Dietary restrictions and drug interactions with monoamine oxidase inhibitors: an update. (2012) (90)
- Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and Age (2011) (89)
- Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial. (2003) (88)
- Clonidine in the Treatment of ADHD: Questions about Safety and Efficacy (1995) (87)
- Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges (2008) (82)
- Comparison of Duloxetine, Escitalopram, and Sertraline Effects on Cytochrome P450 2D6 Function in Healthy Volunteers (2007) (81)
- Predicting asparaginase‐associated pancreatitis (2007) (80)
- The Star‐Allele Nomenclature: Retooling for Translational Genomics (2007) (80)
- Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants (2006) (79)
- Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. (2009) (77)
- Patient‐reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy (2014) (76)
- A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer. (2000) (76)
- Association of polymorphisms of angiogenesis genes with breast cancer (2008) (75)
- Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. (2002) (75)
- Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. (1998) (74)
- Studies on the structure and mechanism of activation of the guanosine 3':5'-monophosphate-dependent protein kinase. (1978) (74)
- Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. (2010) (73)
- Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. (2000) (73)
- CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. (2004) (72)
- Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer (2012) (71)
- Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer (2011) (71)
- Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19 (1997) (71)
- In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. (2010) (71)
- In Vitro Cytochrome P450-Mediated Metabolism of Exemestane (2011) (71)
- Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort (2009) (69)
- In vivo and in vitro phosphorylation of rat liver fructose-1,6-bisphosphatase. (1977) (68)
- In Silico and In Vitro Identification of MicroRNAs That Regulate Hepatic Nuclear Factor 4α Expression (2012) (68)
- Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics (2012) (68)
- Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations. (2014) (68)
- Endothelial nitric oxide synthase haplotypes are related to blood pressure elevation, but not to resistance to antihypertensive drug therapy (2006) (67)
- A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese. (2012) (67)
- Studies on the phosphorylation and dephosphorylation of L-type pyruvate kinase by the catalytic subunit of cyclic AMP-dependent protein kinase. (1980) (66)
- Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples. (2003) (64)
- The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents (2012) (63)
- Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. (2013) (63)
- Selection of Drugs to Treat Gastro-Oesophageal Reflux Disease (2000) (63)
- Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6. (1998) (62)
- Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects (2000) (61)
- Enantiomers of naringenin as pleiotropic, stereoselective inhibitors of cytochrome P450 isoforms. (2011) (60)
- Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing? (2009) (59)
- Creating and evaluating genetic tests predictive of drug response (2008) (59)
- Molecular basis of cardiovascular drug metabolism: implications for predicting clinically important drug interactions. (2000) (59)
- 2010 guide to psychiatric drug interactions (2004) (57)
- Determination of CYP2C19 phenotype in black Americans with omeprazole: Correlation with genotype (1996) (56)
- Evaluation of CYP2D6 and Efficacy of Tamoxifen and Raloxifene in Women Treated for Breast Cancer Chemoprevention: Results from the NSABP P1 and P2 Clinical Trials (2011) (55)
- Genetic associations with taxane-induced neuropathy by a genome-wide association study (GWAS) in E5103. (2011) (54)
- Modeling hot flushes and quality of life in breast cancer survivors (2011) (54)
- Pharmacogenetics in the treatment of breast cancer (2004) (54)
- Guide to Psychiatric Drug Interactions (2006) (54)
- Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. (2012) (52)
- Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer (2016) (51)
- Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol. (2001) (51)
- Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. (2008) (51)
- Human sympathetic activation by α2‐adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450–mediated drug metabolism (2004) (50)
- Morbid obesity and metabolic syndrome in Ossabaw miniature swine are associated with increased platelet reactivity (2011) (50)
- Synthesis of mixed (E,Z)-, (E)-, and (Z)-norendoxifen with dual aromatase inhibitory and estrogen receptor modulatory activities. (2013) (49)
- In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms (2000) (49)
- Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. (2004) (49)
- Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer (2013) (49)
- Effect of cirrhosis and liver transplantation on the gender difference in QT interval. (2005) (47)
- Cancer Pharmacogenomics and Pharmacoepidemiology: Setting a Research Agenda to Accelerate Translation (2010) (47)
- Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. (2000) (46)
- Cytochrome P450 3A pharmacogenetics: the road that needs traveled (2003) (45)
- Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity. (2016) (44)
- Visual Hallucination and Tremor Induced by Sertraline and Oxycodone in a Bone Marrow Transplant Patient (2001) (44)
- Drug interactions, cardiac toxicity, and terfenadine: from bench to clinic? (1996) (43)
- An integrated pharmacokinetics ontology and corpus for text mining (2013) (43)
- Studies on functional domains of the regulatory subunit of bovine heart adenosine 3':5'-monophosphate-dependent protein kinase. (1980) (42)
- Effect of cyclic nucleotide analogs on intrachain site I of protein kinase isozymes. (1982) (42)
- Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100 (2014) (41)
- ATP analog specificity of cAMP-dependent protein kinase, cGMP-dependent protein kinase, and phosphorylase kinase. (1984) (41)
- Teaching rational prescribing: a new clinical pharmacology curriculum for medical schools (2002) (40)
- Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4′-methanol-bisbenzonitrile in vitro (2009) (40)
- Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects. (2007) (40)
- Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy (2009) (40)
- Estrogen Receptor Genotypes, Menopausal Status, and the Lipid Effects of Tamoxifen (2008) (39)
- In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles. (2015) (38)
- Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole (2015) (37)
- A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients? (2008) (37)
- Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6 (2003) (37)
- Cypiripi: exact genotyping of CYP2D6 using high-throughput sequencing data (2015) (36)
- Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics (2002) (36)
- Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case–control study (2010) (36)
- Impact of the Interaction between 3′-UTR SNPs and microRNA on the Expression of Human Xenobiotic Metabolism Enzyme and Transporter Genes (2012) (35)
- Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity (2009) (35)
- Rapid Identification of the Hepatic Cytochrome P450 2C19 Activity Using a Novel and Noninvasive [13C]Pantoprazole Breath Test (2009) (35)
- A modulated empirical Bayes model for identifying topological and temporal estrogen receptor α regulatory networks in breast cancer (2011) (35)
- Regulation of MicroRNA Expression by Rifampin in Human Hepatocytes (2013) (34)
- Differential quantification of CYP2D6 gene copy number by four different quantitative real-time PCR assays (2010) (34)
- The Effects of Tamoxifen and Its Metabolites on Platelet Function and Release of Reactive Oxygen Intermediates (2005) (34)
- CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer (2013) (33)
- Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes (2006) (31)
- Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activities. (2015) (30)
- Olanzapine-Induced Rhabdomyolysis (2001) (30)
- Pharmacogenetic characteristics of the eosinophilia‐myalgia syndrome (1994) (30)
- Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects (2013) (30)
- Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes (2014) (29)
- Improving the quality of adverse drug reaction reporting by 4th‐year medical students (2003) (29)
- Comparative Risk of Ischemic Stroke Among Users of Clopidogrel Together With Individual Proton Pump Inhibitors (2015) (28)
- Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping index. (2013) (27)
- Comparison of Changes in the Lipid Profile of Postmenopausal Women With Early Stage Breast Cancer Treated With Exemestane or Letrozole (2012) (27)
- Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone (1998) (27)
- Cytochrome P450 2D6 and Homeobox 13/Interleukin-17B Receptor: Combining Inherited and Tumor Gene Markers for Prediction of Tamoxifen Resistance (2008) (27)
- Stereoselective metabolism of cisapride and enantiomer-enantiomer interaction in human cytochrome P450 enzymes: major role of CYP3A. (2001) (25)
- Germline pharmacogenetics of tamoxifen response: have we learned enough? (2007) (25)
- Pharmacotherapy and Pregnancy: Highlights from the Third International Conference for Individualized Pharmacotherapy in Pregnancy (2009) (25)
- Formal education about medication errors in internal medicine clerkships. (2001) (25)
- Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover (2015) (25)
- Methadone: A Substrate and Mechanism-Based Inhibitor of CYP19 (Aromatase) (2010) (24)
- Comparison of subjective and objective hot flash measures over time among breast cancer survivors initiating aromatase inhibitor therapy (2009) (24)
- The Need for Translational Research on Drug–Drug Interactions (2012) (24)
- Stereoselective pharmacokinetics of stable isotope (+/-)-[13C]-pantoprazole: Implications for a rapid screening phenotype test of CYP2C19 activity. (2011) (22)
- Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers (1999) (22)
- Indexing pharmacogenetic knowledge on the World Wide Web. (2003) (22)
- Association Between the CYP 3 A 5 Genotype and Blood Pressure (2005) (22)
- Severe hypoglycemia in users of sulfonylurea antidiabetic agents and antihyperlipidemics (2016) (22)
- Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin (2013) (21)
- Investigation of the subcellular distribution of cyclic-AMP phosphodiesterase in rat hepatocytes, using a rapid immunological procedure for the isolation of plasma membrane. (1979) (21)
- Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in post-menopausal patients with breast cancer (2016) (21)
- Influence of Oral Progesterone Administration on Drug-Induced QT Interval Lengthening: A Randomized, Double-Blind, Placebo-Controlled Crossover Study. (2016) (20)
- Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors That Also Modulate Estrogen Receptors. (2016) (20)
- Drug–drug interaction prediction: a Bayesian meta‐analysis approach (2007) (20)
- Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins. (2014) (20)
- Assessment of vascular effects of tamoxifen and its metabolites on the rat perfused hindquarter vascular bed. (2009) (20)
- Pharmacogenomically actionable medications in a safety net health care system (2016) (20)
- Intramuscular Haloperidol or Lorazepam and QT Intervals in Schizophrenia (2004) (20)
- C-reactive protein and fibrin clot strength measured by thrombelastography after coronary stenting (2013) (20)
- QT analysis: a complex answer to a ‘simple’ problem (2004) (20)
- Functional Characterization of a Genetic Polymorphism in the Promoter of the ESR2 Gene (2012) (19)
- Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response (2012) (19)
- Pharmacogenetics of Drug Metabolism (2017) (18)
- Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependent on clopidogrel response. (2012) (17)
- CYP2D6 genotype and tamoxifen response (2005) (17)
- Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel response (2013) (17)
- Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype-dependent (2013) (17)
- A SNP in steroid receptor coactivator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in bone. (2012) (16)
- Inhibition of Cytochrome P450 Enzymes by the E- and Z-Isomers of Norendoxifen (2013) (16)
- Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy (2015) (16)
- Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice. (2001) (16)
- Enhanced Sensitivity to Drug‐Induced QT Interval Lengthening in Patients With Heart Failure Due to Left Ventricular Systolic Dysfunction (2012) (16)
- Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease (2014) (15)
- Clinically Relevant Pharmacology of Neuropsychiatric Drugs Approved Over the Last Three Years: Part II (2006) (15)
- Creating incentives for genomic research to improve targeting of therapies (2004) (15)
- Ticlopidine inhibits phenytoin clearance (1999) (15)
- Sensitive assay for pimozide in human plasma using high-performance liquid chromatography with fluorescence detection: application to pharmacokinetic studies. (1997) (15)
- Effect of CYP3A inhibition on vesnarinone metabolism in humans * (1998) (14)
- Pharmacokinetics of Ibutilide in Patients with Heart Failure Due to Left Ventricular Systolic Dysfunction (2008) (14)
- Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy (2009) (14)
- A new Suzuki synthesis of triphenylethylenes that inhibit aromatase and bind to estrogen receptors α and β. (2016) (14)
- PharmGKB summary: ifosfamide pathways, pharmacokinetics and pharmacodynamics (2014) (14)
- Chapter 12 – PREPARATION OF THE CATALYTIC SUBUNIT OF cAMP-DEPENDENT PROTEIN KINASE1 (1984) (14)
- Pharmacogenetics and healthcare outcomes in patients with chronic heart failure (2012) (14)
- Tamoxifen Downregulates Ets Oncogene Family Members ETV4 and ETV5 in Benign Breast Tissue: Implications for Durable Risk Reduction (2011) (13)
- S‐Mephenytoin hydroxylation phenotypes in a Jordanian population (1995) (13)
- Exploratory study evaluating the association of polymorphisms of angiogenesis genes with hot flashes (2009) (13)
- Induction of Testosterone Metabolism by Esomeprazole in aCYP2C19*2 Heterozygote (2004) (13)
- CYP2D6 genotyping and the pharmacogenetics of tamoxifen. (2008) (12)
- Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers. (2016) (12)
- Aromatase inhibitors augment nociceptive behaviors in rats and enhance the excitability of sensory neurons (2016) (12)
- Pharmacotherapy and Pregnancy: Highlights from the Second International Conference for Individualized Pharmacotherapy in Pregnancy (2009) (12)
- Functional characterization of the 5′‐regulatory region of human CYP2C19 (2003) (12)
- Sequence diversity and functional characterization of the 5'-regulatory region of human CYP2C19. (2003) (11)
- Pharmacokinetics of Fluvoxamine in Relation to CYP2C19 Phenotype and Genotype (2002) (11)
- Cytochrome P450 2D6 status predicts breast cancer relapse in women receiving adjuvant tamoxifen (Tam). (2006) (11)
- Genome-wide discovery of genetic variants affecting tamoxifen sensitivity and their clinical and functional validation. (2013) (11)
- Substantial Effect of Efavirenz Monotherapy on Bilirubin Levels in Healthy Volunteers (2014) (11)
- Stereoselective determination of cisapride, a prokinetic agent, in human plasma by chiral high-performance liquid chromatography with ultraviolet detection: application to pharmacokinetic study. (2000) (10)
- Removal of phosphate from proteins by the reverse reaction. (1983) (10)
- Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF 423 Regulation of BRCA 1 Expression : Individualized Breast Cancer Prevention (2013) (9)
- Is personalized medicine achievable in obstetrics? (2014) (9)
- Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers (2016) (9)
- Single Isomer Versus Racemate: Is There a Difference? Clinical Comparisons in Allergy and Gastroenterology (2002) (9)
- Steroid Pathway Genes and Neonatal Respiratory Distress After Betamethasone Use in Anticipated Preterm Birth (2016) (9)
- Is (+)-[13C]-pantoprazole better than (±)-[13C]-pantoprazole for the breath test to evaluate CYP2C19 enzyme activity? (2012) (9)
- Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer (2017) (9)
- Antiestrogen pathway (aromatase inhibitor). (2009) (9)
- Platelet factor XIIIa release during platelet aggregation and plasma clot strength measured by thrombelastography in patients with coronary artery disease treated with clopidogrel (2015) (9)
- Enhancing Race‐Based Prescribing Precision with Pharmacogenomics (2007) (9)
- Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing. (2007) (9)
- Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors (2017) (8)
- Tamoxifen and Its Metabolites Cause Acute Vasorelaxation of Aortic Rings by Inducing Vasodilator Prostanoid Synthesis (2011) (8)
- A Mixture Model Approach in Gene–Gene and Gene–Environmental Interactions for Binary Phenotypes (2008) (8)
- Discussion: a fresh look at monoamine oxidase inhibitors for depression. (2012) (8)
- Pharmacotherapy and Pregnancy (2009) (7)
- The IGNITE network: a model for genomic medicine implementation and research (2015) (7)
- Reduced Methadone Clearance During Aromatase Inhibition (2012) (7)
- In silico and in vitro identification of microRNAs that regulate HNF 4 A expression (2012) (7)
- Principles of Pharmacogenetics and Pharmacogenomics: Contributors (2011) (6)
- Stereoselective inhibition of CYP2D6 by chlorpheniramine (1995) (6)
- The unfinished business of U.S. drug safety regulation. (2006) (6)
- A distinct inflammatory marker pattern in patients with aromatase inhibitor (AI)-induced musculoskeletal symptoms. (2009) (6)
- FDA's draft guidance on laboratory‐developed tests increases clinical and economic risk to adoption of pharmacogenetic testing (2015) (6)
- Big Data: Challenges and opportunities for clinical pharmacology (2016) (6)
- Methadone adverse reaction presenting with large increase in plasma methadone binding: a case series (2011) (5)
- Pharmacogenomics in Pregnancy (2013) (5)
- Eosinophilia-myalgia syndrome not associated with the ingestion of nutritional supplements. (1994) (5)
- Chapter 21 – Pharmacogenetics of Drug Metabolism (2009) (5)
- Abstract S3-02: Associations between baseline patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor (AI) therapy (2013) (5)
- Identification and characterization of human cytchrome P450 (CYP) isoforms interacting with cisapride (1999) (5)
- Comparative risk of severe hypoglycemia among concomitant users of thiazolidinedione antidiabetic agents and antihyperlipidemics. (2016) (5)
- Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. (2009) (5)
- In Vitro Inhibition of Pimozide N-Dealkylation by Selective Serotonin Reuptake Inhibitors and Azithromycin (2002) (5)
- Breast cancer pharmacogenomics: where we are going. (2012) (5)
- Clinical implications of genetic polymorphism of CYP2D6 in Mexican Americans. (2004) (4)
- Crossover from one aromatase inhibitor (AI) to another in the Exemestane and Letrozole Pharmacogenetics (ELPh) trial. (2016) (4)
- Genome-wide discovery of genetic variants affecting tamoxifen sensitivity and their clinical and functional validation. (2013) (4)
- Amlodipine – not a significant contributor to clopidogrel non-response? (2013) (4)
- The effect of CYP 2D6 genotype and CYP2D6 inhibitors on tamoxife. (2004) (4)
- Clinically Relevant Pharmacology of Neuropsychiatric Drugs Approved Over the Last Three Years: Part I (2006) (4)
- Simultaneous administration of high-dose atorvastatin and clopidogrel does not interfere with platelet inhibition during percutaneous coronary intervention (2016) (4)
- CALMODULIN AND CALMODULIN-BINDING PROTEINS IN NORMAL AND VIRUS-TRANSFORMED FIBROBLASTS: LEVELS, SUBCELLULAR DISTRIBUTION, AND REGULATION1 (1982) (3)
- Tamoxifen-induced hot flashes are associated with estrogen receptor polymorphisms (2007) (3)
- Abstract PD05-02: Genome-Wide Associations of Breast Events and Functional Genomic Studies in High-Risk Women Receiving Tamoxifen or Raloxifene on NSABP P1 and P2 Prevention Trials. A Pharmacogenomics Research Network-RIKEN-NSABP Collaboration (2010) (3)
- Cytochrome P450 (CYP) 2A6 Genetic Variation Predicts Letrozole Plasma Concentrations in Postmenopausal Women with Breast Cancer. (2009) (3)
- One size fits one: pharmacogenetics in gastroenterology. (2014) (3)
- A phase II prospective trial correlating progression-free survival (PFS) with CYP2D6 activity in patients with metastatic breast cancer treated with tamoxifen: ECOG-ACRIN E3108. (2016) (3)
- Faculty Opinions recommendation of Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. (2008) (3)
- CYP 2 B 6 , CYP 3 A 4 , AND CYP 2 C 19 ARE RESPONSIBLE FOR THE IN VITRO N-DEMETHYLATION OF MEPERIDINE IN HUMAN LIVER MICROSOMES (2004) (3)
- Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium ‘Breast Cancer – the Development and Validation of New Therapeutics’ (2005) (3)
- Erratum: Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients (Journal of Clinical Pharmacology (2010) 50: 4 (450-458) DOI: 10.1177/0091270009359182) (2010) (3)
- Thalidomide pharmacokinetics do not change with chronic administration (1997) (3)
- Report of new haplotype for ABCC2 gene: rs17222723 and rs8187718 in cis. (2015) (3)
- Estimating a Positive False Discovery Rate for Variable Selection in Pharmacogenetic Studies (2007) (3)
- P450 Metabolism in Fibromyalgia (1995) (3)
- Whole Genome Amplification of DNA for Genotyping Pharmacogenetics Candidate Genes (2012) (3)
- A Penalized Mixture Model Approach in Genotype/Phenotype Association Analysis for Quantitative Phenotypes (2010) (3)
- Evaluating drugs after their approval for clinical use. (1994) (2)
- Characterization of tamoxifen metabolism to a novel, putative active metabolite (2001) (2)
- Working Group on Pharmacogenetic Testing of CYP 2 C 9 , VKORC 1 Alleles for Warfarin Use : (2008) (2)
- Cytochrome P450 Polymorphisms and their Relationship with Premature Ovarian Failure in Premenopausal Women with Breast Cancer Receiving Doxorubicin and Cyclophosphamide (2011) (2)
- A Genome-Wide Association Study in Patients Experiencing Musculoskeletal Adverse Events on Aromatase Inhibitors as Adjuvant Therapy in Early Breast Cancer Entered on NCIC CTG Trial MA.27. A Pharmacogenetics Research Network-RIKEN Collaboration. (2009) (2)
- In vitro letrozole N‐dealkylation is mainly catalyzed by human cytochrome P450 (CYP) 3A (2005) (2)
- Validating CYP2D6 Genotype-Guided Tamoxifen Therapy for a Multiracial U.S. Population. (2009) (2)
- Immunological Isolation of Hepatocyte Plasma Membranes (1978) (2)
- Abstract P4-02-01: Correlations between Genetic Variants in CYP2D6 and UGT2B7 and Survival in Breast Cancer Patients Treated with or without Tamoxifen: Results from a Large Cohort Study (2010) (2)
- Chapter 13 – Clinical Pharmacogenetics (2007) (1)
- Estrogen receptor genotype is associated with platelet inhibition after tamoxifen treatment (2006) (1)
- Comment on: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. Authors' reply (2004) (1)
- Abstract 4460: Aromatase inhibition by active tamoxifen metabolites (2011) (1)
- Method for the determination of 5,5-diphenylbarbituric acid and its separation from 1,3-dimethoxymethyl-5,5-diphenylbarbituric acid in plasma by high-performance liquid chromatography. (1998) (1)
- The incidence of genetic polymorphisms of CYP 2C in a Korean population (1997) (1)
- Mechanism-based inactivation of CYP2C19 and CYP2D6 by tamoxifen (TAM) and its metabolite n-desmethyltamoxifen (NDTAM) (2001) (1)
- Abstract P1-08-11: Association of variants in candidate genes on lipid profiles in women with early breast cancer on adjuvant aromatase inhibitor therapy (2013) (1)
- An integrated pharmacokinetics ontology and corpus for text mining (2013) (1)
- Pharmacogenomics in admixed populations: the Brazilian pharmacogenetics/pharmacogenomics network—REFARGEN (2004) (1)
- Abstract P1-03-02: CYP2D6 intermediate metabolizers includes patient groups with distinct metabolic activity (2015) (1)
- Effect of Roux-en-Y Gastric Bypass Surgery on the Metabolism of the Orally Administered Medications (2011) (1)
- Metabolism of pimozide by CYF3A and CYP2D6 in human liver microsomes (1997) (1)
- Comprehensive CYP2D6 genotyping in a multiracial population shows differences in allele frequencies between races. (2011) (1)
- Coprescription of paroxetine with tamoxifen to reduce hot flashes reduced plasma 4-hydroxy-N-desmethyl-tamoxifen plasma concentrations in a CYP2D6-dependent manner (2001) (1)
- PI‐24 (2006) (1)
- Overview of the pharmacokinetics of fluvoxamine. Discussion (1995) (1)
- Germline pharmacogenomics as a tool to individualize therapy in breast cancer (2009) (1)
- Cloning and sequencing of 5′-regulatory region of CYP2C19 (2001) (1)
- Endoxifen has antiestrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. (2004) (1)
- Abstract PD10-08: Venlafaxine inhibits the CYP2D6 mediated metabolic activation of tamoxifen: Results of a prospective multicenter study: (NCT00667121) (2012) (1)
- An Update on MAOIs: Dietary Restrictions and Drug Interactions (2012) (1)
- Effect of grapefruit juice (GFJ) on the stereo-selective pharmacokinetics (PK) of cisapride (CIS) and cardiac qtc interval in healthy volunteers (2001) (1)
- Thiotepa is a specific inhibitor of cytochrome P450 2B6 Implications for cyclophosphamide metabolism (2002) (1)
- Interaction of Calmodulin with cAMP Dependent Protein Kinase in Brain (1982) (1)
- Protease Activated Receptor-1 (PAR-1) Mediated Platelet Aggregation is Dependant on Clopidogrel Response (2014) (0)
- Role of CYP3A4 and CYP2B6 in the in vitro N‐demethylation of meperidine (2004) (0)
- CYP genotypes influence the effect of tamoxifen therapy on serum lipids (2004) (0)
- Abstract 2451: Increased Myocardial Sensitivity to IKr Inhibition in Patients With Heart Failure Due to Left Ventricular Systolic Dysfunction (2009) (0)
- In vitro inhibition of tricyclic antidepressants (TCAs) on phenytoin P-hydroxylation: Involvement of CYP2C9 and CYP2C19 (2001) (0)
- In vitro metabolism of toborinone by human liver cytochrome P450 isoforms (1998) (0)
- Does Roux-en-Y Gastric Bypass Affect the Metabolism of the Orally Administered Medications?: 2010 Presidential Poster: 225 (2010) (0)
- S1588 Cirrhotic Patients with TIPS Are At Risk for Medication Induced QT Prolongation (2009) (0)
- CYP2D6 poor metabolizers in depressed women of Mexican origin (2004) (0)
- First-in-Class Product Seeks To Promote Better Prescribing Habits (2009) (0)
- Microarray analysis of drug metabolizing enzyme induction in primary hepatocyte cultures (2001) (0)
- In Vitro P 450-Mediated Metabolism of Exemestane (2010) (0)
- Abstract 18453: Morbid Obesity and Metabolic Syndrome in Ossabaw Swine Are Associated with Increased Responsiveness of Platelets to Various Agonists (2010) (0)
- Effect of selective serotonin reuptake inhibitors (SSRIS) and clonidine on the secondary metabolism of tamoxifen (TAM) by genetically polymorphic CYP2D6 (2001) (0)
- Indiana Biobank (IB) (2011) (0)
- Breast Cancer Tamoxifen Dose Escalation in Patients With Diminished CYP 2 D 6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity (2016) (0)
- [Importance of pharmacogenetics in antiretroviral metabolism and drug-transporters]. (2011) (0)
- Pharmacogenetic testing ofCYP2C9andVKORC1 alleles for warfarin (2008) (0)
- Abstract P5-12-05: CYP3A4*22 polymorphism is associated with increased exemestane concentrations in postmenopausal breast cancer patients (2016) (0)
- Identification and Characterization of Human Cytochrome P 450 Isoforms Interacting with Pimozide 1 (1998) (0)
- Oxandrolone-Warfarin Interactions (2004) (0)
- Special Section on Epigenetic Regulation of Drug Metabolizing Enzymes and Transporters Regulation of MicroRNA Expression by Rifampin in Human Hepatocytes s (2013) (0)
- Phase I I E valuation o f T halidomide i n P atients W ith Metastatic B reast C ancer (2000) (0)
- In vitro inhibition of pimozide N-dealkylation by selective serotonin reuptake inhibitors (SSRIS) antidepressants and azithromycin (2001) (0)
- Factor XIII Val 34 Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease (2014) (0)
- Oral Session I (OI) Population‐Based Advances in Pharmacotherapy 10:45 am – 12:00 Noon (2014) (0)
- 2004 GuidetoPsychiatric Drug Interactions (2004) (0)
- Editors' report for 2014, November 2014 (2015) (0)
- DMD052886 1763..1768 (2013) (0)
- INFLUENCE OF PROGESTERONE ADMINISTRATION ON DRUG-INDUCED TORSADES DE POINTES IN AV NODE-ABLATED ISOLATED PERFUSED RABBIT HEARTS (2016) (0)
- Tamoxifen Metabolism, SSRIs, and the Cancer Patient (2008) (0)
- Genetic variants associated with toxicity-related discontinuation of adjuvant aromatase inhibitor (AI) therapy. (2012) (0)
- Pharmacogenetics and healthcare outcomes in patients with chronic heart failure (2012) (0)
- The association between CYP3A5 genotype and antihypertensive response (2004) (0)
- Principles of Pharmacogenetics and Pharmacogenomics: Introduction (2012) (0)
- Effect of Roux-en-Y Gastric Bypass on the Pharmacodynamic Response to Orally Administered Drugs (2011) (0)
- Immunological isolation of hepatocyte plasma membranes [proceedings]. (1978) (0)
- The Disposition of Reduced Haloperidol and HPP,+ Metabolites of Haloperidol, is Not Influenced by P-Glycoprotein (2006) (0)
- Oral Session I (2015) (0)
- The association between the CYP3A5 genotype and blood pressure (2004) (0)
- Conversion of dimethoxymethyl-diphenylbarbituric acid (DMMDPB) to diphenylbarbituric acid (DPB) in the rat (1996) (0)
- Abstract P5-12-06: Comprehensive assessment of the effect of genetic polymorphisms in drug metabolizing enzymes and transporters on tamoxifen activation to endoxifen (2016) (0)
- OIV‐B‐3 (2006) (0)
- Lack of effect of insulin on guanosine 3':5'-cyclic monophosphate content of insulin-sensitive rat hepatocytes [proceedings]. (1979) (0)
- Abstract 1875: Identifying genetic variants contributing to cellular susceptibility to tamoxifen using a genome-wide cell-based model (2012) (0)
- Phase II Evaluation Of Thalidomide In Patients With Metastatic Breast Cancer (2001) (0)
- Associations between treatment-emergent symptoms and early discontinuation of aromatase inhibitor (AI) therapy. (2015) (0)
- Presidential Trainee Awards (PT 1–13) (2012) (0)
- Abstract 3604: Significant effect of polymorphisms in CYP2D6 and DT-1 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients (2010) (0)
- Abstract 18740: Influence of Oral Progesterone Administration on QT Interval Response to Ikr Inhibition (2014) (0)
- In vivo and in vitro phosphorylation of rat liver fructose-1 , 6-bisphosphatase ( hexosediphosphatase / protein kinase / gluconeogenic enzyme / cyclic AMP ) (0)
- Editors' report, November 2013. (2014) (0)
- Omeprazole (OPZ) as a Probe for the CYP2C19 Polymorphism in an African‐American (AA) Population (1996) (0)
- Halofantrine Safety, Tolerance and Metabolism Studies. (1997) (0)
- In reply [2] (2006) (0)
- Germline pharmacogenomics in the treatment of breast cancer (2008) (0)
- Phase-I study of hepapoietin on liver function (2000) (0)
- Pharmacogenetic determinant of cyclophosphamide therapy in patients with lupus nephritis (2003) (0)
- Associations between estrogen receptor (ER) Alpha expression levels and ER genotypes. (2009) (0)
- Abstract 4306: Simultaneous Administration of High Dose Atorvastatin and Clopidogrel Loading Doses Does Not Interfere With Platelet Inhibition During Percutaneous Coronary Intervention (2009) (0)
- Editors' Report for 2015, December 2015. (2016) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With David Alastair Flockhart?
David Alastair Flockhart is affiliated with the following schools: